Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.46 |
| ▸ | VDR | P11473 | 2/20 | 0.45 |
| ▸ | THRA | P10827 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18376354 | 0.88 | MAPT (0.61) | MAPTSMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL18376419 | 0.86 | MAPT (0.63) | MAPTSMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL18376352 | 0.85 | MAPT (0.62) | MAPTSMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL18376420 | 0.84 | MAPT (0.75) | MAPTSMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL18376279 | 0.84 | MAPT (0.59) | MAPTSMN1; SMN2MEN1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL18763561 | 0.83 | MAPT (0.73) | MAPTSMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL5752686 | 0.82 | HTR1A (0.60) | MEN1KMT2AMAPK14ACKR3HTR1A | |
| SCHEMBL18376269 | 0.80 | MAPT (0.72) | MAPTSMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL18779465 | 0.80 | MAPT (0.61) | MAPTSMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL18779401 | 0.79 | MEN1 (0.63) | MAPTSMN1; SMN2MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548894-B2 | Benzamide or benzamine compounds useful as anticancer agents for the treatment of human cancers | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-01-10 | — | — | US | disclosed |
| US-20190263820-A1 | BENZAMIDE OR BENZAMINE COMPOUNDS USEFUL AS ANTICANCER AGENTS FOR THE TREATMENT OF HUMAN CANCERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-08-29 | — | — | US | disclosed |
| US-10112948-B2 | Benzamide or benzamine compounds useful as anticancer agents for the treatment of human cancers | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-10-30 | — | — | US | disclosed |
| US-20170114062-A1 | BENZAMIDE OR BENZAMINE COMPOUNDS USEFUL AS ANTICANCER AGENTS FOR THE TREATMENT OF HUMAN CANCERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-04-27 | — | — | US | disclosed |
| US-20170114062-A1 | BENZAMIDE OR BENZAMINE COMPOUNDS USEFUL AS ANTICANCER AGENTS FOR THE TREATMENT OF HUMAN CANCERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112948-B2 | Benzamide or benzamine compounds useful as anticancer agents for the treatment of human cancers | ACAT1, ACAT2, NPC1L1 | MAPT 4323/4885SMN1; SMN2 4636/4885MEN1 603/4885 |
| US-20190263820-A1 | BENZAMIDE OR BENZAMINE COMPOUNDS USEFUL AS ANTICANCER AGENTS FOR THE TREATMENT OF HUMAN CANCERS | ACAT1, ACAT2, NPC1L1 | MAPT 4323/4885SMN1; SMN2 4636/4885MEN1 603/4885 |
| US-11548894-B2 | Benzamide or benzamine compounds useful as anticancer agents for the treatment of human cancers | ACAT1, ACAT2, NPC1L1 | MAPT 4323/4885SMN1; SMN2 4636/4885MEN1 603/4885 |
| US-20170114062-A1 | BENZAMIDE OR BENZAMINE COMPOUNDS USEFUL AS ANTICANCER AGENTS FOR THE TREATMENT OF HUMAN CANCERS | ACAT1, ACAT2, NPC1L1 | MAPT 4323/4885SMN1; SMN2 4636/4885MEN1 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.